Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study

Background. Nonalcoholic fatty liver disease (NAFLD) is commonly observed in patients with type 2 diabetes (T2D). Semaglutide, a glucagon-like peptide 1 receptor agonist, may have a therapeutic role by targeting common mechanisms involved in the pathophysiology of T2D and NAFLD. The study aimed to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Volpe, Sara, Lisco, Giuseppe, Fanelli, Margherita, Racaniello, Davide, Colaianni, Valentina, Triggiani, Domenico, Donghia, Rossella, Crudele, Lucilla, Rinaldi, Roberta, Sabbà, Carlo, Triggiani, Vincenzo, De Pergola, Giovanni, Piazzolla, Giuseppina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657108/
https://www.ncbi.nlm.nih.gov/pubmed/36364937
http://dx.doi.org/10.3390/nu14214673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657108/
https://www.ncbi.nlm.nih.gov/pubmed/36364937
http://dx.doi.org/10.3390/nu14214673

Ejemplares similares